• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

作者信息

Gutteridge Eleanor, Robertson John F R

机构信息

Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham, HG5 1PB, UK.

出版信息

Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18.

DOI:10.1186/bcr2443
PMID:20030876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2797704/
Abstract
摘要

相似文献

1
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.当前的药物研发项目是否正在充分发挥新药物的全部潜力？酪氨酸激酶抑制剂。
Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18.
2
Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.双靶点/泛HER酪氨酸激酶抑制剂：聚焦于乳腺癌
Adv Exp Med Biol. 2006;587:329-40. doi: 10.1007/978-1-4020-5133-3_25.
3
Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.表皮生长因子受体（EGFR）与人类表皮生长因子受体2（Her2）联合阻断作为乳腺癌临床治疗策略的早期成效
Cancer Biol Ther. 2004 Jun;3(6):490.
4
Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.用于治疗肺癌和乳腺癌的不可逆多靶点表皮生长因子受体（ErbB）家族抑制剂
Curr Cancer Drug Targets. 2015;14(9):775-93. doi: 10.2174/1568009614666141111104643.
5
Lapatinib: a sword with two edges.拉帕替尼：一把双刃剑。
Pathol Oncol Res. 2008 Mar;14(1):1-8. doi: 10.1007/s12253-008-9018-z. Epub 2008 Apr 12.
6
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.双重激酶抑制在乳腺癌治疗中的应用：表皮生长因子受体/ErbB-2抑制剂拉帕替尼的初步经验
Oncologist. 2004;9 Suppl 3:10-5. doi: 10.1634/theoncologist.9-suppl_3-10.
7
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?小分子酪氨酸激酶抑制剂拉帕替尼在乳腺癌治疗中算得上是一项突破吗？
Breast Cancer. 2007;14(2):156-62. doi: 10.2325/jbcs.971.
8
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.曲妥珠单抗与 EGFR/HER-2 酪氨酸激酶抑制剂在 HER-2 阳性乳腺癌细胞中的协同作用。
Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16.
9
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.表皮生长因子受体1和表皮生长因子受体2通路抑制在乳腺癌治疗中的未来：靶向多种受体
Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1.
10
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.酪氨酸激酶抑制剂增强多药耐药底物抗癌药物在肺癌细胞系中的细胞毒性，而与生长因子受体状态无关。
Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5.

本文引用的文献

1
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.吉非替尼在他莫昔芬耐药和激素不敏感型乳腺癌中的作用：一项 II 期研究。
Int J Cancer. 2010 Apr 15;126(8):1806-1816. doi: 10.1002/ijc.24884.
2
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
3
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.曲妥珠单抗和吉非替尼联合阻断ErbB受体网络用于HER2（ErbB2）过表达转移性乳腺癌患者的I-II期研究。
Clin Cancer Res. 2008 Oct 1;14(19):6277-83. doi: 10.1158/1078-0432.CCR-08-0482.
4
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.一项关于新辅助阿那曲唑单药或联合吉非替尼治疗早期乳腺癌的II期安慰剂对照试验。
J Clin Oncol. 2007 Sep 1;25(25):3816-22. doi: 10.1200/JCO.2006.09.6578. Epub 2007 Aug 6.
5
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.雌激素受体阳性、HER-2/neu阳性乳腺癌模型中肿瘤消退及对雌激素剥夺和氟维司群耐药的机制
Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045.
6
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.拉帕替尼：一种用于癌症治疗的新型表皮生长因子受体/人表皮生长因子受体2酪氨酸激酶抑制剂
Drugs Today (Barc). 2006 Jul;42(7):441-53. doi: 10.1358/dot.2006.42.7.985637.
7
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.绝经后雌激素受体阳性且表皮生长因子受体阳性的原发性乳腺癌患者术前使用吉非替尼与吉非替尼联合阿那曲唑的疗效比较：一项双盲安慰剂对照的II期随机试验
Lancet Oncol. 2005 Jun;6(6):383-91. doi: 10.1016/S1470-2045(05)70176-5.
8
EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.非小细胞肺癌中的表皮生长因子受体（EGFR）突变可能预示着对吉非替尼的反应：一种新兴模式的扩展。
Adv Anat Pathol. 2005 Mar;12(2):47-52. doi: 10.1097/01.pap.0000155052.68496.e4.
9
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.一项关于吉非替尼用于经紫杉烷和蒽环类药物预处理的转移性乳腺癌的多中心II期研究。
Breast Cancer Res Treat. 2005 Jan;89(2):165-72. doi: 10.1007/s10549-004-1720-2.
10
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.肺癌中人类表皮生长因子受体抑制剂的现状概述
Clin Lung Cancer. 2004 Dec;6 Suppl 1:S7-S19. doi: 10.3816/clc.2004.s.009.